Search

Guido D Pollevick

from North Bergen, NJ
Age ~58
Get Report
Also known as:
Goido D Pollevick
Related to:
Federico Pollevick, 26Matias E Pollevick, 29
Connected to:
Amy C Pollex, 42Richard G Pollex, 76Alice L Polley, 81Cara J Polley, 41Cathy S Polley, 66Charlotte S Polley, 81Cindy L Polley, 59Claire Polley, 29Daniel Polley, 50Howard W Polley, 57

Guido Pollevick Phones & Addresses

  • North Bergen, NJ
  • 8 Chestnut Ridge Way, Dobbs Ferry, NY 10522 (914) 478-1353
  • 12 Oxford Rd, New Hartford, NY 13413 (315) 733-8462

Work

Company: Transgenomic - New Heaven, CT Dec 2010 Position: Director of operations

Education

School / High School: University of Buenos Aires- Buenos Aires, Buenos Aires 1990 Specialities: Ph.D. in Chemical Sciences

Resumes

Resumes

Guido Pollevick Photo 1

Guido Pollevick Dobbs Ferry, NY

View page
Work:
Transgenomic
New Heaven, CT
Dec 2010 to Mar 2012
Director of Operations
PGxHealth
New Heaven, CT
May 2007 to Dec 2010
Laboratory Director
Masonic Medical Research Laboratory
Utica, NY
Nov 2002 to May 2007
Laboratory Director
Laboratorios Gentronic
Buenos Aires, Buenos Aires
Dec 1999 to Nov 2002
Laboratory Director
Education:
University of Buenos Aires
Buenos Aires, Buenos Aires
1990 to 1994
Ph.D. in Chemical Sciences

Publications

Us Patents

Cacnb2 Nucleic Acid Mutations As Indicators Of Shorter Than Normal Qt Interval And St Segment Elevation Associated With Sudden Cardiac Death

View page
US Patent:
7968296, Jun 28, 2011
Filed:
Oct 8, 2010
Appl. No.:
12/901070
Inventors:
Charles Antzelevitch - New Hartford NY, US
Guido Pollevick - Dobbs Ferry NY, US
International Classification:
C12Q 1/68
C07H 21/00
C07K 14/435
C07K 14/705
US Classification:
435 617, 435 912, 536 235, 536 2431, 530350
Abstract:
Previously unknown mutations of the CACNA1C and CACNB2b genes are disclosed which are involved in ion channel disruptions associated with shorter than normal QT interval and ST segment elevation syndrome. These mutations are utilized to diagnose and screen for shorter than normal QT interval and ST segment elevation syndrome, thus providing modalities for diagnosing syncope and/or sudden cardiac death and/or predicting susceptibility to syncope and/or sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant polypeptides described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations.

Loss Of Function Mutations In Calcium Channel Polypeptides Associated With Sudden Cardiac Death

View page
US Patent:
20080118438, May 22, 2008
Filed:
Nov 6, 2007
Appl. No.:
11/983005
Inventors:
Charles Antzelevitch - New Hartford NY, US
Guido Pollevick - Dobbs Ferry NY, US
International Classification:
A61K 49/00
C07H 21/04
C07K 16/00
C12Q 1/68
C12N 15/00
A61P 43/00
C12N 5/00
C40B 40/06
C12Q 1/00
US Classification:
424 92, 536 235, 530350, 435 6, 536 2431, 4353201, 435325, 5303879, 506 16, 435 4
Abstract:
Previously unknown mutations of the CACNA1C and CACNB2b genes are disclosed which are involved in ion channel disruptions associated with shorter than normal QT interval and ST segment elevation syndrome. These mutations are utilized to diagnose and screen for shorter than normal QT interval and ST segment elevation syndrome, thus providing modalities for diagnosing syncope and/or sudden cardiac death and/or predicting susceptibility to syncope and/or sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant polypeptides described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations.
Control profile
Guido D Pollevick from North Bergen, NJ, age ~58 Get Report